Method for treatment of urogenital infections that are sexually transmitted and caused by chlamydiae and/or micoplasma
SUBSTANCE: invention is referred to the field of medicine, namely to dermatovenerology and immunology and can be used for treatment of patients with sexually transmitted urogenital infections caused by chlamydiae and/or micoplasma. It includes the infusion of antibiotics of macrolides group or immunotropic drug that is selected individually, for which purpose the sensitivity of patient to immunotropic drugs is determined. That is done by in vitro definition of interferons in the samples of peripheral blood and urogenital scrapings before and after addition of each studies drug. As the result the immunotropic drug selected for treatment is the one that induces the increase of interferon activity in studied material by no less than 4 U/ml compared to the baseline level in the samples of peripheral blood and urogenital scrapings.
EFFECT: method provides for etiologic recovery, prevention of disease relapses, particularly due to effective interferons production on systemic and local level.
1 dwg, 4 tbl, 5 ex
The invention relates to medicine, namely to dermatology and immunology, and can be used for treatment of urogenital infections, sexually transmitted and caused by chlamydia and/or mycoplasmas.
Modern studies have confirmed the significant role of immune mechanisms in the development of the urogenital infectious diseases [Rakovsky IV // Mycoplasma person and mycoplasmal infections (Lecture. Part 1 and II) // Clinically. lab. diag-ka. - 2005. No. 2. No. 3. - C-32].
Clinical observations have shown that the treatment of urogenital diseases is complicated by the persistent nature of current infections and relapses approximately 10-15% of cases. This fact has served as justification for the imposition of immunotropic drugs in the treatment of chlamydial infections of the urogenital tract [Gomberg M.A., Chernousov A.D., Soloviev A.M. // the Use of immunotherapy in the management of patients with infection caused by Chlamydia trachomatis. // STIs. - 2001. No. 5. - P.48. Kamaganova IV, S. Khromov, Cooks J.F. ñ // is the Complex treatment of complicated chlamydia // Consilium medicum. - 2005. - P.9-10].
There is a method of treatment of urogenital chlamydial infections with the use of adjuvant therapy, including immunotropic drug superlymph and antibiotic setrole the macrolides, we adopted for the prototype [kamaganova I. Khromov the S., Cooks J.F. ñ //is the Complex treatment of complicated chlamydia // Consilium medicum. - 2005. However, the lack of individual approach to the choice of immunotropic drugs leads in some cases to the recurrence of diseases of the urogenital tract. The disadvantages of existing methods of treatment can be attributed to the lack of assessment of individual sensitivity to immunotropic drugs peripheral blood cells and scrapings of the urogenital tract of the patient.
The objective of the invention is the development of effective treatment of urogenital infectious diseases caused by chlamydia and/or mycoplasmas.
The technical result is to achieve etiological recovery and relapse prevention by determining individual sensitivity to the immunotropic drugs and accounting for the production of interferon in systemic and local levels.
The essence of the invention is that in the treatment of urogenital infectious diseases, sexually transmitted and caused by chlamydia and/or mycoplasmas, appoint immunotropic drug and an antibiotic of the macrolide group. Pre-determine sensitivity to immunotropic drugs. With this purpose in samples of peripheral blood and the scrapings of the urogenital tract determine the activity of interferon before and after adding each of the CSOs of the study drug. In the choose the immunotropic a drug that induces increased activity of interferons in the studied material not less than 4 IU/ml compared with baseline levels.
The method is as follows.
1. The clinical examination of the patient samples are scraping the urogenital tract, as well as samples of peripheral blood collected from the cubital vein with a solution of an anticoagulant. One of the samples of scraping the urogenital tract and sent to the molecular-genetic analysis (the polymerase chain reaction, PCR) to establish an etiologic diagnosis. Another sample of scraping, as well as a sample of peripheral blood of the patient is examined for sensitivity to immunotropic drugs for their effect on the production of interferons.
To do this, in 96-well tablets make cells peripheral blood or cell scrapings of the urogenital tract, diluted with medium RPMI-1640, at a concentration of 2×106/ml.
2. In a sample of cells add one of the tested immunotropic drugs: immunal, neovir, superlymph in different concentrations of 1:10, 1:100 and doses of 1 or 10 μg/ml
3. In accordance with the scheme of the experiment, the wells included the following reagents: 1) cells in peripheral blood (control, raw data); 2) cells scraping (control, raw data); 3) cell accessories the historical blood + test drug; 4) cells swab + test drug.
4. Tablets incubated in CO2-incubator at 37°C for 24 h Then separated from the supernatant and tested for the presence of activity of interferons (IFN).
5. Titration for determining the activity is carried out in 96-well flat-bottomed tablets, for example, the culture of diploid human fibroblasts grown in the growth medium prior to the formation of monolayer. As an indicator of test virus using virus encephalomyocarditis mice (vamc).
6. When considering the results choose the immunotropic a drug that induces increased activity of interferon is not less than 4 IU/ml compared with baseline levels.
For evidence of a possible implementation of the stated purpose and achievement of the technical result here is the following data.
Patient P, 24 years old, came with the purpose of investigating the presence of sexually transmitted infections. At the time of inspection subjective feelings are absent, discharge from the urethra in appearance and the volume does not differ from the physiological norm. The use of PCR has allowed to detect the presence of Chlamydia trachomatis + Ureaplasma.urealyticum. Thus, the patient was diagnosed with urogenital chlamydial Ureaplasma infection.
Diagnostic survey activity interf the Ronov in samples of clinical material and the scrapings were not found.
Before therapy was determined by the sensitivity of peripheral blood cells and scrapings UHT to immunotropic drugs to immunolo, Nibiru, superlymph. For this selection of immunotropic drugs for their effect on the production of interferon. Revealed the sensitivity of blood cells (4 U/ml) and scrapings UHT (8 U/ml) to superlymph. Sensitivity to immunolo was detected only when the action on blood cells (4 U/ml) (table 1). Negative results were obtained by testing the sensitivity of blood cells and scrapings UHT to Nibiru (table 1). This was the basis for inclusion superlymph in the complex therapy. The patient was prescribed superlymph, suppositorie scheme: 25 ED 1 candle 25 UNITS at night, the course of 10 days.
After applying superlymph the PCR results showed the absence of U.urealyticum, however, were identified .trachomatis. Subsequent appointment jozamitina at a dose of 500 mg to 1 t × 3 times/day course of 10 days.
Application jozamitina to the lack of C.trachomatis in the scraping of the urogenital tract. Thus, in the complex therapy superlymph and dzhozamitsin were not detected by the method of Poland chlamydia and Ureaplasma. Etiological recovery, confirmed by PCR, was maintained for 3 months, and then in the course of the year. Thus, during the year the patient had not been marked by relapses and what Ecodom PCR not detected chlamydia and Ureaplasma.
Patient F., 28 years old, came to survey for the presence of sexually transmitted infections. He reported that the sexual partner identified chlamydial infection. Previously, the patient was examined and was not treated. At the time of inspection subjective feelings are absent, discharge from the urethra in appearance and the volume does not differ from the physiological norm. Application of PCR method allowed to detect the presence of Chlamydia trachomatis + Mycoplasma genitalium and to establish the diagnosis of chlamydial and Mycoplasma infection. The results of the evaluation of interferon status showed that the patient's production of interferon in systemic and local levels were not found.
The patient revealed sensitivity to immunotropic drugs: superlymph (blood samples and scrapings), immunolo (blood sample), Nibiru (scrape)that was the basis of the inclusion superlymph in the complex therapy (table 2). The patient was prescribed superlymph, suppositorie at a dose of 25 UNITS on 1 suppository for the night, the course of 10 days. At the beginning of therapy superlymph the patient noted some redness, swelling in the area of the urethra that was associated with antimicrobial action superlymph - suppress the excessive growth of the bacterial flora of the urogenital tract, (staphylococci, enterococci, yeast-like fungi, and others). On okonchan and application superlymph these phenomena were completely resolved. However, after therapy superlymph in the scraping of the patient were again detected chlamydia and Mycoplasma. Along with this, the patient had increased activity interferoninducible cells.
The patient was scheduled therapy roxithromycin at a dose of 500 mg 1 tab. 3 times/day course of 10 days. The application jozamitina C.trachomatis and Mycoplasma genitalium were not detected in the scraping of the urogenital tract using PCR method.
Etiological recovery, confirmed by PCR, was maintained for 3 months, and then during the year of observation.
Thus, during the year the patient had no recurrence and PCR were not detected chlamydia and Mycoplasma.
The Patient Br., 22 years old, came about vaginal discharge observed during 1.5 years. Diagnostic examination by PCR detected Mycoplasma genitalium, Ureaplasma urealyticum, and Gardnerella vaginalis. The original level of activity of interferon was reduced. The patient without selection immunotropic drug was prescribed therapy with superlymph suppositories dose of 25 UNITS on 1 suppository for the night, the course of 10 days. After the end of therapy superlymph PCR were again detected Mycoplasma, Ureaplasma and gardnerelly against the background of significant vaginal dysbiosis. The patient had survived the initial reduced level is aktivnosti interferon in the blood samples and scrapings UHT. Along with this, the identified violations of the composition of the microflora UHT.
The patient was scheduled therapy roxithromycin at a dose of 500 mg 1 tab. 3 times/day course of 10 days. The application jozamitina PCR were found out gardnerelly. At the same time, bacteriological examination showed a reduction in the levels of lactobacilli. After 3 months of observations by PCR newly discovered gardnerelly, the purpose of therapy without selection immunotropic drug did not lead to an etiological recovery. PCR were found gardnerelly. Marked characteristic vaginal dysbiosis within the next 3 months.
Patient C., 30 years old, came with the purpose of investigating the presence of urogenital infections, sexually transmitted diseases. At the time of the survey subjective feelings are absent. Application of PCR method allowed to detect the presence of Mycoplasma.hominis + U.urealyticum. Evaluation of interferon status of the patient showed that the initial activity of interferons in the studied cells in peripheral blood and scrapes UHT were not found.
Before therapy in blood samples and scrapings revealed the sensitivity of cells to superlymph, immunolo and Nibiru (table 3). The patient was prescribed therapy with neovia - one of the drugs of choice. Neovir was administered in a dose of 250 mg with 2 ml of 0.5% solution of novocaine is, every 48 h, a course of 10 injections.
After therapy neovia in the scraping of the urogenital tract PCR detected Mycoplasma, was reduced level of production of interferon by peripheral blood cells and scrapings UHT.
The patient was scheduled therapy roxithromycin at a dose of 500 mg 1 tab. 3 times/day course of 10 days. The application jozamitina were not detected by PCR Mycoplasma and Ureaplasma. In addition, the sensitivity to immunotropic drugs persisted.
Etiological recovery, confirmed by PCR, was maintained for 3 months, and then in the course of the year. In a patient after therapy neovia and roxithromycin during the year is not marked by relapses and PCR not detected M.hominis and U.urealyticum.
Patient B., 31, filed in connection with the fact that the sexual partner during the examination in female consultations identified Mycoplasma infection. At the time of inspection subjective feelings are absent, discharge from the urethra in appearance and the volume does not differ from the physiological norm. Application of PCR method allowed to detect the presence of M.hominis and Gardnerella vaginalis.
When evaluating interferon status before therapy decreased activity production of IFN in blood samples and scrapings UHT.
Before terap is in her blood samples and scrapings UHT revealed the sensitivity of cells to superlymph (table 4). The patient was prescribed therapy with concomitant administration of superlymph and jozamitina. Schema therapy: superlymph suppositories dose of 25 ED no 1 candle on the night, jozamitsin at a dose of 500 mg 1 tab. 3 times/day, a course of 10 days. In therapy superlymph + jozamitsin PCR were not detected Mycoplasma and gardnerelly. However, the patient noted a decrease of the production of interferons on the system and local levels. Etiological recovery, confirmed by PCR, was maintained for 3 months, and then in the course of the year.
Thus, the use of the proposed method in 52 patients, 25 men and 27 women with urogenital infectious diseases, sexually transmitted diseases and activated chlamydia and/or mycoplasmas, was made the selection of immunotropic drug effect on secretion of interferons in samples of peripheral blood and scrapes UHT. In all cases (32 patients received first therapy superlymph, then roxithromycin; 20 patients received simultaneously superlymph + jozamitsin) achieved etiological recovery during the year there was no recurrence. Sensitivity to immunotropic drugs was associated with suppression of the high level of growth associated microflora and restore nor the social composition of microflora of UHT, and with the increased activity of interferons detected in samples of peripheral blood and the scrapings of the urogenital tract on the system and local levels. The method improves the efficiency of treatment, relapse prevention and lengthening the time of remission.
A method of treating urogenital infectious diseases, sexually transmitted and caused by chlamydia and/or mycoplasmas, including the appointment of immunotropic drug, antibiotic groups, macrolide, wherein the pre-determined sensitivity to immunotropic drugs, which determine the in vitro activity of interferons in samples of peripheral blood and the scrapings of the urogenital tract before and after adding each of the studied drugs and choose the immunotropic a drug that induces increased activity of interferon is not less than 4 IU/ml compared to baseline levels in a sample of peripheral blood and the scraping of the urogenital tract.
SUBSTANCE: invention can be used for embryo quality prediction preceding conducting the extracorporeal fertilisation program in infertile women mediated by tuboperitoneal factor and external genital endometriosis. Peripheral venous blood of an infertile women is examined for the HLA-DR+ MON% value, and if the derived value is 68% or more, transferring a high-quality embryo is predicted, while the value being less shows transferring a low-quality embryo.
EFFECT: examining women suffering tuboperitoneal factor and external genital endometriosis under the declared method shall enable the pre-fertilisation embryo quality prediction and well-timed prescription of adequate therapeutic measures.
1 tbl, 3 ex
SUBSTANCE: what is offered is an expression construct for expression of single- or multipass transmembrane polypeptides in a bacterial host cell. Said construct contains a protein-coding polynucleotide, a strictly sensitive promoter of lower basal activity in the host-cell, and a leader sequence comprising a translation initiation enhancer. The strictly sensitive promoter comprises at least one positive control element and at least one negative control element. One or more positive and negative control elements represent a heterologous control element. Besides, what is offered is a method for producing the expressed transmembrane polypeptide and a method of recovering it form the host cell.
EFFECT: methods provide producing the high-yield transmembrane polypeptides either of native conformation, or in a soluble form.
53 cl, 28 dwg, 5 tbl, 10 ex
SUBSTANCE: concentration of serotonin in patient's blood serum is determined. If quantitative content of serotonin is from 100 to 200 ng/ml concussion of brain is diagnosed, and if value of parameter is from 200 ng/ml and higher - injury of brain.
EFFECT: method application makes it possible to increase accuracy of differential diagnostics of concussion and injury of brain.
SUBSTANCE: invention refers to medicine, namely oncology, and can be used for determining time to lung cancer progression. For this purpose, lung tumour tissue after curative resection and intact lung tissue obtained from a tumour remote site are analysed for a prolactin level, and if observing the value increasing in 1.5 times or more relatively to that in the intact lung tissue the generalised process and the onset of metastatic lung cancer to remote organs within 6 months is predicted.
EFFECT: method allows the objective assessment of the pathological process directionality, the well-timed prediction of the generalised cancer and taking adequate therapeutic measures.
SUBSTANCE: in women in tissue of lung malignant tumour after radical surgery in pulmonectomy volume and in intact lung tissue, obtained from ablated from lung section of the same lung, level of progesterone is determined. If it reduces in tumour in 5 times and more relative the level of progesterone in intact lung tissue, development of cerebral lung cancer metastases in women within the term from 3 to 8 months is predicted.
EFFECT: possibility of early prediction of development of cerebral metastases in women with lung cancer, which gives possibility of take adequate preventive therapeutic measures.
SUBSTANCE: on 6-12 week of gestation in peripheral venous blood of pregnant women with threat of miscarriage before treatment relative content of CD4+CD25+ lymphocytes is determined and if its value is less than 4.0%, short-term effect of standard preserving therapy is predicted, and if value equals 4.0% and higher, prolonged effect of preserving therapy and course of pregnancy without threat of abortion in 2 and 3 trimesters is predicted.
EFFECT: application of method makes it possible to increase accuracy of standard preserving therapy of threat of pregnancy abortion at early terms of gestation, which will make it possible to timely correct therapeutic and preventive measures and prevent development of late miscarriage.
3 ex, 1 tbl
SUBSTANCE: in patient obtaining basic anti-inflammatory therapy with combination of inhalation glucocorticosteroid and β2-aginist of long action, level of obtaining control of bronchial asthma is determined by criteria GINA 2006. After that, additionally determined is expression of CD20 marker. If CD20 expresses 16% and more, carried out anti-asthmatic therapy is considered ineffective, requiring correction, if less than 16% of cells - effective.
EFFECT: application of method makes it possible to subjectively estimate efficiency of carried out anti-asthmatic therapy with combination of IGC and β2-aginist of long action.
1 tbl, 1 ex
SUBSTANCE: in newborn babies with intrauterine pneumonia, who are on artificial lung ventilation, content of protein of cells Clara (CC 16) is analyses on the 3-5-th day of life in single portion of bronchoalveolar lavage and if its value is less than 53 ng/ml, development of bronchopulmonary dysplasia is predicted, when there are no clinical manifestations. Claimed method possesses high accuracy, sensitivity, specificity.
EFFECT: application of method makes it possible to timely administrate adequate therapy and contributes to reduction of economic expenditure on treatment and prevents disorders in child's health state in future.
2 tbl, 3 ex
SUBSTANCE: strain was isolated from the pig which died in LLP "Gorkaya Balka" in Soviet district of Stavropol region during disease epizootic in 2008. Strain is new, earlier unknown, isolated on the territory of RF and is designated as strain "Stavropol 01/08". It possesses high infectious activity, accumulates in cultures of bone marrow cells of pigs and pigs' leukocytes in titre 6.0-7.0 lg HAU50 cm3. Virus titre on pigs constitutes 7.0-7.5 lg LD50 cm3. Death of infected pigs occurs with symptoms characteristic of acute form of ASP 3-6 days after manifestation of clinical symptoms of disease. Invention can be used in research institutions and diagnostic centres as reference-strain in carrying out virological, molecular-genetic and monitoring research.
EFFECT: high infectious activity of strain.
3 tbl, 3 ex
SUBSTANCE: immunocytochemical estimation method for proliferative lymphocyte state by an expression behaviour of an C-terminal B23/nucleophosmin protein fragment in indirect immunofluorescence test provides a visual cell estimation for count and size of luminous nucleoli marked by a specific anti-peptide antibody to the C-terminal B23/nucleophosmin protein fragment detecting a B23.1 protein oligomer form only of molecular weight 210-230 kDa. The intact lymphocyte value found in a cycling state G0 is the presence in a cell nucleus of no more than one luminous nucleoli detected by the specified C-fragment B23 antibody, while 2-3 luminous nucleoli are detected in lymphocytes in the process of proliferative lymphocyte activity caused by PHA stimulation in 24 hours from the initiation of the stimulation procedure, and 4-5 luminous nucleoli of greater size and more intense luminescence between + to +++ as compared with the reference are detected in the cells in 48-72 hours from the initiation of the stimulation procedure when most lymphocytes are found at the peak of proliferative activity in the cycling state S.
EFFECT: invention enables early diagnostics of malignant haematological and oncological diseases.
3 dwg, 1 tbl, 2 ex
SUBSTANCE: invention describes novel compounds of general formula in which is or (values of radicals are given in the claim), a method of producing said compounds, a pharmaceutical composition containing said compounds and therapeutic application thereof.
EFFECT: compounds are cysteine protease inhibitors and can be used in medicine.
25 cl, 1 tbl, 41 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly immunology, namely immunocorrection drugs, and can be used as an inducer of a granulocyte-macrophage colony-forming factor in cells of a mononuclear phagocyte system in vitro and for efferent therapy in pathological conditions accompanied by decrease in cell-mediated immunity. The drug represents oxidised dextrane of average molecular weight 35 - 65 kDa. The drug can be presented in the form of a solution or a nanoliposomal emulsion of the concentration of oxidised dextrane 1-5 wt %. The drug is applied by introduction in a cell culture of the mononuclear phagocyte system in an amount containing oxidised dextrane 125-250 mcg per culture medium 1 ml.
EFFECT: drug under the invention exhibits high biocompatibility.
8 cl, 1 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns an immunomodulatory drug preparation showing antiviral properties. Substance of the invention consists in the fact that the offered drug preparation contains sodium nucleinate 2 to 50 mg/ml, sodium chloride 3 to 10 mg/ml and apyrogenic water with pH making within 6.0 to 7.5.
EFFECT: preparation has a direct antiviral effect, suppresses reproductive ability of viruses.
2 cl, 3 ex, 3 tbl
SUBSTANCE: group of inventions refers to medicine, namely to allergology, and can be used for prevention of development of respiratory allergies in a subject. That is ensured by introduction of an effective amount of Lactobacillus rhamnosus GG (LGG) either in a pregnant mother's body, and/or postnatal in a feeding mother's body, or in a subject directly.
EFFECT: introduction of LGG allows preventing an early allergic sensitisation and the following development of respiratory allergies due to higher production of serum antibodies IgA in a subject, and also prevention of allergic inflammation in lungs and respiratory ways.
12 cl, 13 ex, 9 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to optimised fused protein for blocking BLyS or APRIL, which contains extracellular region of N-end of truncated TACI (transmembrane activator and CAML-partner) and Fc sequence IgG. TACI segment of fused protein contains sequence of amino-end region of extracellular region, starting with 13-th amino acid residue, complete sequence of stem area from TACI and is obtained from native sequence of TACI between 12-th and 120-th amino acids. Segment Fc of immunoglobulin IgG of fused protein contains hinge region, CH2 region and CH3 region, TACI segment and Fc segment are fused either directly or through linker sequence. In addition, claimed is DNA sequence which codes fused protein, expression vector, host-cell, pharmaceutical composition, containing fused protein, and application of fused protein for blocking BLyS or APRIL. Obtained fused protein does not degrade in process of expression, possesses high biological activity and high level of expression.
EFFECT: fused protein in accordance with claimed invention can be used in treatment of diseases, associated with abnormal immunologic functions and in treatment of diseases caused by abnormal proliferation of B-lymphocytes.
10 cl, 6 dwg, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to immunomodulatory interleukin-1 drugs. An interleukin composition contains interleukin-1, a cyclooxygenase inhibitor - diclofenac, taken in certain proportions.
EFFECT: compositions exhibit higher efficacy and have no side effects.
6 cl, 5 tbl, 6 ex
SUBSTANCE: invention relates to a compound of formula (I), where m equals 1-2, and each R1 (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, hydroxy-(2-6C)alkoxy, amino-(2- 6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, hydroxy-(2-6C)alkylamino, halogen-(2-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy and heterocyclylamino, where heterocyclyl is a 3-7-member monocyclic saturated ring containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, wherein the heterocyclyl can have 1-2 substitutes defined in claim 1, and any of the substitutes R1 given above, which contains a CH3 group bonded to a carbon or nitrogen atom, can contain a substitute given in claim 1, R2 is a halogen, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, and R4 is hydroxy, (1-6C)alkyl or (1-6C)alkoxy; or pharmaceutically acceptable salts thereof. The invention also relates to methods for synthesis of said compounds, pharmaceutical compositions based on said compounds, and use of said compounds in treating diseases or medical conditions mediated by cytokines.
EFFECT: more effective use of the compounds.
13 cl, 8 tbl, 15 ex
SUBSTANCE: invention relates to a compound of formula
or pharmaceutically acceptable salt thereof, where symbols assume the following values; ring denotes
or , X denotes a single bond, -CH2-, -NR3-, -O-, -S-, R1 denotes a halogen; phenyl; pyridyl; (C3-C8)cycloalkyl; or (C1-C6) alkyl or (C2-C6) alkenyl, each of which can contain a halogen, -CONH2, phenyl or (C3-C8)cycloalkyl as a substitute, R2 denotes CN, -O-(C1-C6)alkyl, -C(=O)H, halogen; or (C1-C6)alkyl, which can be substituted with a halogen or -OH, R3 can form morpholino or 1-pyrrolidinyl together with R1 and nitrogen, and when X denotes a single bond, R1 and R2 can jointly form a 5-member ring and additionally contain -(C1-C6)alkyl as a substitute, R4 denotes the following ring: , , , , , , , , , , or , where any one of the bonds in the ring is linked to an oxazole ring, R5 denotes -H, (C1-C6)alkyl, which can be substituted by not less than one group selected from: -C(=O)NRXRY, -NHRX and -ORX- (C2-C6)alkenyl-; -C(=O)H; -C(=O)NRXRY, RX and RY can be identical or different and denote -H; or (C1-C6)alkyl. The invention also relates to a pharmaceutical composition based on said compounds, having SlP1 agonist activity.
EFFECT: compounds and compositions can be used in medicine for preventing and treating rejection during organ transplant, bone marrow or tissue transplant and autoimmune diseases.
16 cl, 84 tbl, 198 ex
SUBSTANCE: invention refers to medicine, also aims at treating babies suffering intestinal colics. A mother and a breast-fed child are treated simultaneously. A cephalosporin antibiotic, an antistaphylococcal immunoglobulin, a staphylococcal bacteriophage, an antifungal agent, a phagocytosis activator are prescribed in the mother for 7-10 days. A staphylococcal bacteriophage, Hylak forte are prescribed to the baby. The second stage involves prescribing a bacterial preparation, an immunomodulator and a therapeutic staphylococcal anatoxin. The baby intakes Hylak forte and the bacterial preparation.
EFFECT: method allows relieving intestinal colics and preventing the development of complications.
SUBSTANCE: invention relates to medicine, namely, to immunology and clinic laboratory diagnostics, and can be used to predict course of acute respiratory viral infections (ARVI) in children in the first days of disease and timely administration of immunomodulating medications. For this purpose by means of ELISA immunologic indices of spontaneous and induced interferon-γ in vitro (IFH-γ) are determined. Index of interferon-γ stimulation (IS IFH-γ) is calculated by division of index of induced level by index of spontaneous level of interferon-γ. Also carried out is calculation of lymphocyte activation index (LAI IFH-γ) per 1000 lymphocytes by division of index of induced interferon-γ by absolute number of patient's lymphocytes. Additionally in blood plasma determined is content of interleukin-10 (IL-10). If values of IS IFH-γ are higher than 3, LAI IFH-γ equals or is higher than 40, IL-10 is from 30 to 60 pg/ml favourable outcome of disease is predicted with therapeutic treatment which does not include immunomodulators. If IS IFH-γ is lower than 3, LAI IFH-γ is lower than 40, IL-10 is from 60 to 100 pg/ml, predicted are severe course of disease and development of complications, which requires urgent treatment by immunomodelling therapy. If IS IFH-γ is lower than 3, LAI IFH-γ is lower than 30, IL-10 is higher than 100 pg/ml, predicted are severe course of disease with development of bronchopulmonary complications and possible chronisation of pathologic process and recurrent ARVD, which requires additional introduction of immunomodelling medications.
EFFECT: increase of accuracy of early prediction of disease course severity and development of complications in children with ARVI, including those from 1 month old, which makes it possible to carry out necessary anti-viral and immunomodelling therapy, aimed at strengthening immunity cell responses, in due time.
3 tbl, 3 ex
FIELD: food industry.
SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases.
EFFECT: improvement of infant health without risks of adverse allergic reaction.
25 cl, 2 dwg, 3 tbl, 1 ex